公开(公告)号：US12241065B2

公开(公告)日：2025-03-04

申请号：US16961578

申请日：2019-01-11

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C12N15/113 ,  A61K9/00 ,  A61K31/7088 ,  A61K39/395

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US11713316B2

公开(公告)日：2023-08-01

申请号：US17164009

申请日：2021-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Louis S. Chupak ,  Chetan Padmakar Darne ,  Min Ding ,  Robert G. Gentles ,  Yazhong Huang ,  Manjunatha Narayana Rao Kamble ,  Scott W. Martin ,  Raju Mannoori ,  Ivar M. McDonald ,  Richard E. Olson ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Gopikishan Tonukunuru ,  Sivasudar Velaiah ,  Jayakumar Sankara Warrier ,  Xiaofan Zheng ,  John S. Tokarski ,  Bireshwar Dasgupta ,  Kotha Rathnakar Reddy ,  Thiruvenkadam Raja

IPC: C07D403/04 ,  C07D471/04 ,  C07D487/04 ,  A61K31/196

CPC classification number: C07D471/04

Abstract: Disclosed are compounds of Formula (I):




or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20220324859A1

公开(公告)日：2022-10-13

申请号：US17164009

申请日：2021-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Louis S. Chupak ,  Chetan Padmakar Darne ,  Min Ding ,  Robert G. Gentles ,  Yazhong Huang ,  Manjunatha Narayana Rao Kamble ,  Scott W. Martin ,  Raju Mannoori ,  Ivar M. McDonald ,  Richard E. Olson ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Gopikishan Tonukunuru ,  Sivasudar Velaiah ,  Jayakumar Sankara Warrier ,  Xiaofan Zheng ,  John S. Tokarski ,  Bireshwar Dasgupta ,  Kotha Rathnakar Reddy ,  Thiruvenkadam Raja

IPC: C07D471/04

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US11058767B2

公开(公告)日：2021-07-13

申请号：US16282138

申请日：2019-02-21

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Brian R. Anderson ,  Peter Hagedorn ,  Marianne Lerbech Jensen ,  Ivar M. McDonald ,  Stephen E. Mercer

IPC: C07H21/02 ,  C07H21/04 ,  A61K39/395 ,  A61K47/54 ,  A61K47/64 ,  A61K47/60 ,  A61P9/12 ,  A61P9/04 ,  A61K9/00 ,  C12N5/074 ,  C12N5/077 ,  C12N15/113 ,  A61K31/713 ,  A61K39/00

Abstract: The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.

公开(公告)号：US09822144B2

公开(公告)日：2017-11-21

申请号：US15587715

申请日：2017-05-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yong Zhang ,  Ivar M. McDonald ,  Naidu S. Chowdari ,  Tram N. Huynh ,  Robert M. Borzilleri ,  Sanjeev Gangwar

IPC: C07D487/04 ,  C07D519/00 ,  C07K5/062

CPC classification number: C07K5/06052 ,  A61K47/6843 ,  A61K47/6849 ,  C07D487/04 ,  C07D519/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/76

Abstract: Benzodiazepine dimers having a structure represented by wherein R1 is wherein the variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

公开(公告)号：US09708323B2

公开(公告)日：2017-07-18

申请号：US15317546

申请日：2015-06-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ivar M. McDonald ,  F. Christopher Zusi ,  Richard E. Olson

IPC: C07D471/18

CPC classification number: C07D471/18

Abstract: The disclosure provides compounds of formula I including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

公开(公告)号：US12180478B2

公开(公告)日：2024-12-31

申请号：US17815493

申请日：2022-07-27

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C07H21/04 ,  C12N15/113

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US10398783B2

公开(公告)日：2019-09-03

申请号：US15789027

申请日：2017-10-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ivar M. McDonald ,  Prasanna Sivaprakasam ,  Christiana I. Iwuagwu ,  Kevin M. Peese ,  Heng Cheng ,  Naidu S. Chowdari ,  Sanjeev Gangwar

IPC: C07D471/04 ,  A61K47/68 ,  C07D519/00 ,  C07F7/08 ,  C07K5/062

Abstract: A compound capable of inhibiting cell proliferation, having a structure according to formula (I) wherein the variables in formula (I) are as defined in the specification. Such compounds are useful as anti-cancer agents, especially in antibody-drug conjugates.

公开(公告)号：US09822112B2

公开(公告)日：2017-11-21

申请号：US15587679

申请日：2017-05-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ivar M. McDonald ,  Naidu S. Chowdari ,  Walter Lewis Johnson ,  Yong Zhang ,  Robert M. Borzilleri ,  Sanjeev Gangwar

IPC: C07D487/04 ,  C07D519/00 ,  C07D471/04

CPC classification number: C07D471/04 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07D487/04 ,  C07D519/00 ,  C07K5/06052

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

公开(公告)号：US09526801B2

公开(公告)日：2016-12-27

申请号：US14994378

申请日：2016-01-13

Applicant: Bristol-Myers Squibb Company

Inventor： Ivar M. McDonald ,  Naidu S. Chowdari ,  Walter Lewis Johnson ,  Yong Zhang ,  Robert M. Borzilleri ,  Sanjeev Gangwar

IPC: C07D487/04 ,  C07D519/00 ,  A61K47/48 ,  C07K5/062

CPC classification number: C07D471/04 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07D487/04 ,  C07D519/00 ,  C07K5/06052

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract translation: 并且式（I），（Ia）和（Ib）中的其它变量如申请中所定义。 这种二聚体可用作抗癌剂，特别是当用于抗体 - 药物偶联物（ADC）时。